Ghanaian Pharmaceutical Manufacturing – Generic Drug Production

Requirement

A Ghanaian pharmaceutical company seeks $18 million to expand generic drug manufacturing capacity and achieve WHO prequalification for export to regional markets. The investment supports Africa's pharmaceutical self-sufficiency agenda accelerated by COVID-19. Current operations include a WHO-GMP certified facility producing 150+ formulations across tablets, capsules, and liquids. Expansion adds sterile manufacturing capacity for injectables and vaccines, targeting regional and international tender markets. We seek pharmaceutical industry investors, DFIs, and impact funds focused on healthcare access. Investment structure is flexible between growth equity and project finance depending on investor preference. Current ownership includes the founding family and local institutional investors. Africa imports 70%+ of pharmaceutical needs, representing a $15 billion annual market. Ghana offers competitive manufacturing costs, English-speaking workforce, and supportive industrial policy including the African Medicines Agency headquarters. Target returns of 18-22% IRR based on capacity expansion, margin improvement through backward integration, and export market access. WHO prequalification unlocks procurement from major international health organizations.